| Literature DB >> 29432733 |
Takahiro Tomino1, Hirotada Tajiri1, Takaaki Tatsuguchi2, Takahiro Shirai3, Kounosuke Oisaki3, Shigeki Matsunaga4, Fumiyuki Sanematsu5, Daiji Sakata5, Tomoharu Yoshizumi6, Yoshihiko Maehara6, Motomu Kanai3, Jean-François Cote7, Yoshinori Fukui5, Takehito Uruno8.
Abstract
Rac1 is a member of the Rho family of small GTPases that regulates cytoskeletal reorganization, membrane polarization, cell migration and proliferation. Recently, a self-activating mutation of Rac1, Rac1P29S, has been identified as a recurrent somatic mutation frequently found in sun-exposed melanomas, which possesses increased inherent GDP/GTP exchange activity and cell transforming ability. However, the role of cellular Rac1-interacting proteins in the transforming potential of Rac1P29S remains unclear. We found that the catalytic domain of DOCK1, a Rac-specific guanine nucleotide exchange factor (GEF) implicated in malignancy of a variety of cancers, can greatly accelerate the GDP/GTP exchange of Rac1P29S. Enforced expression of Rac1P29S induced matrix invasion and macropinocytosis in wild-type (WT) mouse embryonic fibroblasts (MEFs), but not in DOCK1-deficient MEFs. Consistently, a selective inhibitor of DOCK1 that blocks its GEF function suppressed the invasion and macropinocytosis in WT MEFs expressing Rac1P29S. Human melanoma IGR-1 and breast cancer MDA-MB-157 cells harbor Rac1P29S mutation and express DOCK1 endogenously. Genetic inactivation and pharmacological inhibition of DOCK1 suppressed their invasion and macropinocytosis. Taken together, these results indicate that DOCK1 is a critical regulator of the malignant phenotypes induced by Rac1P29S, and suggest that targeting DOCK1 might be an effective approach to treat cancers associated with Rac1P29S mutation.Entities:
Keywords: Cancer; Cytoskeleton; DOCK1; GEF; Invasion; Rac1
Mesh:
Substances:
Year: 2018 PMID: 29432733 DOI: 10.1016/j.bbrc.2018.02.073
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575